Welcome to our dedicated page for Aditxt SEC filings (Ticker: ADTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aditxt, Inc. filings document the company’s life sciences platform, its common stock capital structure, and material events affecting its operating subsidiaries and public-company status. Recent Form 8-K reports cover the completed acquisition of Ignite Proteomics, related financial statements and pro forma information, senior unsecured promissory notes, at-the-market offering capacity, and Nasdaq listing-compliance matters.
Proxy materials and meeting reports describe board elections, auditor ratification, executive-compensation votes, reverse stock split authority, and other stockholder matters. The filing record also includes disclosures on preferred stock issued in acquisition consideration, equity financing arrangements, governance approvals, and risks associated with maintaining exchange listing standards.
Aditxt, Inc. held its 2026 virtual annual stockholder meeting with 294,398 common shares represented, equal to 34.17% of shares outstanding as of March 26, 2026, establishing a quorum. Stockholders elected five directors, each to serve until the 2027 annual meeting.
They ratified dbbmckennon as independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the compensation of named executive officers. Stockholders also provided advisory input on how often to hold future executive pay votes.
Importantly, stockholders granted the board discretionary authority to implement a reverse stock split of common stock at a ratio between 1-for-2 and up to 1-for-250 within one year of approval, and authorized potential adjournment of the meeting to solicit additional proxies if needed.
HRT Financial LP, a ten percent owner of Aditxt, Inc., reported open-market sales of Class A shares. It sold 29,404 shares at $0.28 per share on April 24, 2026 and 3,811 shares at $0.29 per share on April 23, 2026. After these transactions, HRT Financial LP directly held 88,377 Class A shares.
Aditxt, Inc. filed a prospectus to register up to 148,278,241 shares of Common Stock for resale by selling stockholders, representing shares issuable upon exercise of outstanding warrants. The filing states the warrants have a $0.50 exercise price (Adjustment Price as of the April 7, 2026 adjustment) and that if all warrants were exercised for cash it would yield gross proceeds of approximately $74.14 million to the company. The prospectus confirms the company will not receive proceeds from resale by the selling stockholders; proceeds to the company would arise only if warrants are exercised for cash. The resale program covers multiple warrant series and placement-agent warrants, and includes a 4.99% beneficial ownership limit on warrant exercises (adjustable to 9.99% upon notice). The filing notes Nasdaq listing under the symbol ADTX and a closing share price of $0.347 on April 20, 2026.
HRT Financial LP, a ten percent owner of Aditxt, Inc. (ADTX), reported mixed open-market trades in Class A Shares. It bought 72,912 shares at $0.33 per share on April 21, 2026 and sold 11,982 shares at $0.30 per share on April 22, 2026. After these transactions, HRT Financial LP directly held 121,592 Class A Shares, reflecting a net increase of 60,930 shares.
HRT Financial LP has filed an initial ownership report for Aditxt, Inc. The Form 3 shows HRT Financial as a ten percent owner, directly holding 133,574 Class A Shares following the reported date. The filing records this ownership position rather than any new share purchase or sale.
Aditxt, Inc. entered into a financing deal by issuing and selling senior unsecured promissory notes with an aggregate original principal amount of $1,250,000 to accredited investors for a purchase price of $1,000,000, reflecting a $250,000 original issue discount. The Notes bear 10% annual interest, payable monthly, and are scheduled to mature on September 30, 2026. If Aditxt sells common stock through an at-the-market offering or equity line of credit, all such gross proceeds, net of specified expenses, must be used weekly to redeem the Notes at 120% of the amount redeemed. Upon an event of default, holders can require redemption at 125% of the redeemed amount, and a bankruptcy event triggers immediate payment of 125% of all outstanding principal, interest and late charges, alongside restrictive covenants after maturity.
Aditxt, Inc. registers up to 148,278,241 shares of Common Stock for resale by selling stockholders, representing shares issuable upon exercise of outstanding warrants. The registration covers resale on a resale basis by the identified selling holders.
The Company will not receive proceeds from secondary sales; however, if the warrants are exercised for cash at the current $0.50 exercise price, cash proceeds to the Company would be approximately $74.14 million. The prospectus states the company’s Nasdaq closing price on April 2, 2026 was $0.794 per share.
Aditxt, Inc. filed an amended current report to add full financial statements for its acquisition of Ignite Proteomics LLC and related unaudited pro forma consolidated financials. The deal consideration includes 36,000 shares of Series A-2 Convertible Preferred Stock with an aggregate stated value of $36.0 million.
Ignite’s audited results show modest 2025 revenue of $43,539 and a net loss of $5,701,059, leading to a member’s deficit of $6,807,109 and a going concern warning due to recurring losses and negative operating cash flows. Pro forma balance sheets record preliminary goodwill of $36,551 (in thousands of dollars) related to the transaction.
Aditxt, Inc. is calling a virtual 2026 annual meeting on May 1, 2026 at 12:00 p.m. ET, where holders of common stock as of the March 26, 2026 record date, when 861,482 shares were outstanding, can vote online.
Stockholders will vote on six items: electing five directors for one-year terms; ratifying dbbmckennon as independent auditor for 2026; an advisory “say‑on‑pay” vote on executive compensation; an advisory vote on how often to hold say‑on‑pay, with the board recommending every three years; authorizing the board to implement a reverse stock split within one year at a ratio between 1‑for‑2 and 1‑for‑250; and approving the ability to adjourn the meeting if needed.
The proxy details leadership and compensation, including 2025 base salaries of $500,000 for CEO Amro Albanna, $325,000 for Chief Innovation Officer Shahrokh Shabahang, $385,008 for Chief M&A Officer Corinne Pankovcin, and $395,000 for CFO Thomas Farley, plus change‑in‑control severance protections. It also confirms independent board committees, audit fees, and that the reverse split is intended to support Nasdaq listing and broaden investor appeal.